Employees Retirement System of Texas Takes $36,000 Position in Medpace Holdings, Inc. $MEDP

Employees Retirement System of Texas purchased a new stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 116 shares of the company’s stock, valued at approximately $36,000.

Several other hedge funds and other institutional investors have also bought and sold shares of MEDP. Portside Wealth Group LLC increased its position in shares of Medpace by 2.5% during the 2nd quarter. Portside Wealth Group LLC now owns 1,090 shares of the company’s stock valued at $342,000 after purchasing an additional 27 shares during the last quarter. PDS Planning Inc grew its position in Medpace by 1.5% during the second quarter. PDS Planning Inc now owns 2,421 shares of the company’s stock valued at $760,000 after buying an additional 35 shares during the period. Benjamin Edwards Inc. increased its holdings in Medpace by 3.1% during the first quarter. Benjamin Edwards Inc. now owns 1,201 shares of the company’s stock worth $366,000 after buying an additional 36 shares during the last quarter. Geneos Wealth Management Inc. increased its holdings in Medpace by 64.9% during the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after buying an additional 37 shares during the last quarter. Finally, Assetmark Inc. raised its holdings in shares of Medpace by 24.9% in the 1st quarter. Assetmark Inc. now owns 216 shares of the company’s stock worth $66,000 after purchasing an additional 43 shares during the period. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Insider Activity

In related news, President Jesse J. Geiger sold 21,503 shares of Medpace stock in a transaction on Wednesday, November 5th. The stock was sold at an average price of $595.66, for a total transaction of $12,808,476.98. Following the completion of the sale, the president owned 15,000 shares of the company’s stock, valued at approximately $8,934,900. This trade represents a 58.91% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Susan E. Burwig sold 20,000 shares of the business’s stock in a transaction dated Monday, November 24th. The stock was sold at an average price of $609.15, for a total value of $12,183,000.00. Following the transaction, the vice president owned 27,500 shares of the company’s stock, valued at approximately $16,751,625. The trade was a 42.11% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 317,597 shares of company stock valued at $189,967,248 in the last quarter. 20.30% of the stock is currently owned by company insiders.

Medpace Stock Down 1.2%

Shares of NASDAQ MEDP opened at $599.50 on Friday. The company has a market cap of $16.89 billion, a P/E ratio of 41.92, a P/E/G ratio of 2.67 and a beta of 1.42. Medpace Holdings, Inc. has a 52 week low of $250.05 and a 52 week high of $626.26. The business has a 50-day simple moving average of $560.60 and a two-hundred day simple moving average of $444.37.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Wednesday, October 22nd. The company reported $3.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.50 by $0.36. Medpace had a net margin of 18.36% and a return on equity of 91.88%. The firm had revenue of $659.90 million for the quarter, compared to the consensus estimate of $640.49 million. During the same period in the prior year, the firm posted $3.01 earnings per share. The company’s revenue for the quarter was up 23.7% on a year-over-year basis. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. Equities research analysts anticipate that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Analysts Set New Price Targets

A number of analysts have issued reports on MEDP shares. Wall Street Zen raised Medpace from a “hold” rating to a “buy” rating in a research report on Saturday, October 25th. TD Cowen lifted their price objective on Medpace from $356.00 to $462.00 and gave the stock a “sell” rating in a report on Friday, October 24th. Mizuho increased their target price on shares of Medpace from $575.00 to $655.00 and gave the stock an “outperform” rating in a research report on Friday, October 24th. BMO Capital Markets began coverage on shares of Medpace in a research note on Thursday, November 13th. They issued a “market perform” rating and a $600.00 target price for the company. Finally, Rothschild Redb lowered shares of Medpace from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, September 3rd. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, ten have issued a Hold rating and four have given a Sell rating to the company. According to MarketBeat, Medpace currently has a consensus rating of “Hold” and a consensus target price of $487.18.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.